The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - EMD Serono; Flatiron Health; Gerson Lehrman Group; LEK; Lilly; M3
Research Funding - EMD Serono (Inst); Taiho Pharmaceutical (Inst)
 
Mohammed M. Milhem
Honoraria - Amgen; Blueprint Medicines; Immunocore; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Blueprint Medicines; Immunocore; Trieza Therapeutics
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Christina Kovacs
Employment - Novartis
Travel, Accommodations, Expenses - Novartis
 
Alpesh Amin
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Andrea Magley
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
D. Das Purkayastha
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Sarina Anne Piha-Paul
Research Funding - Abbvie (Inst); Aminex (Inst); Bayer (Inst); BlueLink (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Samumed (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)